Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events-Reference-Cited by-同舟云学术

Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events

Published:2017-11-08 Issue:415 Volume:9 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Ishihara Jun¹²^ORCID,Fukunaga Kazuto¹²³^ORCID,Ishihara Ako¹^ORCID,Larsson Hans M.²,Potin Lambert¹²^ORCID,Hosseinchi Peyman¹^ORCID,Galliverti Gabriele²^ORCID,Swartz Melody A.¹²⁴⁵^ORCID,Hubbell Jeffrey A.¹²⁵^ORCID

Affiliation:

1. Institute for Molecular Engineering, University of Chicago, Chicago, IL 60637, USA.

2. Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.

3. Department of Bioengineering, Tokyo Institute of Technology, 226-8501 Yokohama, Kanagawa, Japan.

4. Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.

5. Institute of Chemical Sciences and Engineering, School of Basic Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.

Abstract

Matrix-binding peptide conjugation to immune checkpoint blockade antibodies enhances antitumor efficacy and reduces adverse events.

Funder

the European Research Commission grant

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference48 articles.

1. The future of immune checkpoint therapy

2. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy